{
    "title": "115_hr5590",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Opioid Addiction Action Plan Act''.\n\nSEC. 2. ACTION PLAN ON RECOMMENDATIONS FOR CHANGES UNDER MEDICARE AND \n              MEDICAID TO PREVENT OPIOIDS ADDICTIONS AND ENHANCE ACCESS \n              TO MEDICATION-ASSISTED TREATMENT.\n\n    (a) In General.--Not later than January 1, 2019, the Secretary of \nHealth and Human Services (in this section referred to as the \n``Secretary''), in collaboration with the Pain Management Best \nPractices Inter-Agency Task Force convened under section 101(b) of the \nComprehensive Addiction and Recovery Act of 2016 (Public Law 114-198), \nshall develop an action plan that provides recommendations described in \nsubsection (b).\n    (b) Action Plan Components.--Recommendations described in this \nsubsection are, based on an examination by the Secretary of potential \nobstacles to an effective response to the opioid crisis, \nrecommendations, as determined appropriate by the Secretary, on the \nfollowing:\n            (1) Recommendations on changes to the Medicare program \n        under title XVIII of the Social Security Act and the Medicaid \n        program under title XIX of such Act that would enhance coverage \n        and payment under such programs of all medication-assisted \n        treatment approved by the Food and Drug Administration for the \n        treatment of opioid addiction and other therapies that manage \n        chronic and acute pain and treat and minimize risk of opioid \n        addiction, including recommendations on changes to the Medicare \n        prospective payment system for hospital inpatient department \n        services under section 1886(d) of such Act (42 U.S.C. \n        1395ww(d)) and the Medicare prospective payment system for \n        hospital outpatient department services under section 1833(t) \n        of such Act (42 U.S.C. 1395l(t)) that would allow for separate \n        payment for such therapies, if medically appropriate and if \n        necessary to encourage development and adoption of such \n        therapies.\n            (2) Recommendations for payment and service delivery models \n        to be tested by the Center for Medicare and Medicaid Innovation \n        and other federally authorized demonstration projects, \n        including value-based models, that may encourage the use of \n        appropriate medication-assisted treatment approved by the Food \n        and Drug Administration for the treatment of opioid addiction \n        and other therapies that manage chronic and acute pain and \n        treat and minimize risk of opioid addiction.\n            (3) Recommendations for data collection that could \n        facilitate research and policy making regarding prevention of \n        opioid addiction and coverage and payment under the Medicare \n        and Medicaid programs of appropriate opioid addiction \n        treatments.\n            (4) Recommendations for policies under the Medicare program \n        and under the Medicaid program that can expand access for \n        rural, or medically underserved communities to the full range \n        of medication-assisted treatment approved by the Food and Drug \n        Administration for the treatment of opioid addiction and other \n        therapies that manage chronic and acute pain and treatment and \n        minimize risk of opioid addiction.\n            (5) Recommendations on changes to the Medicare program and \n        the Medicaid program to address coverage or payment barriers to \n        patient access to medical devices that are non-opioid based \n        treatments approved by the Food and Drug Administration for the \n        management of acute pain and chronic pain, for monitoring \n        substance use withdrawal and preventing overdoses of controlled \n        substances, and for treating substance use disorder.\n    (c) Stakeholder Meetings.--\n            (1) In general.--Beginning not later than 3 months after \n        the date of the enactment of this Act, the Secretary shall \n        convene a public stakeholder meeting to solicit public comment \n        on the components of the action plan recommendations described \n        in subsection (b).\n            (2) Participants.--Participants of meetings described in \n        paragraph (1) shall include representatives from the Food and \n        Drug Administration and National Institutes of Health, \n        biopharmaceutical industry members, medical researchers, health \n        care providers, the medical device industry, the Medicare \n        program, the Medicaid program, and patient advocates.\n    (d) Request for Information.--Not later than 3 months after the \ndate of the enactment of this section, the Secretary shall issue a \nrequest for information seeking public feedback regarding ways in which \nthe Centers for Medicare & Medicaid Services can help address the \nopioid crisis through the development of and application of the action \nplan.\n    (e) Report to Congress.--Not later than June 1, 2019, the Secretary \nshall submit to Congress, and make public, a report that includes--\n            (1) a summary of recommendations that have emerged under \n        the action plan;\n            (2) the Secretary's planned next steps with respect to the \n        action plan; and\n            (3) an evaluation of price trends for drugs used to reverse \n        opioid overdoses (such as naloxone), including recommendations \n        on ways to lower such prices for consumers.\n    (f) Definition of Medication-Assisted Treatment.--In this section, \nthe term ``medication-assisted treatment'' includes opioid treatment \nprograms, behavioral therapy, and medications to treat substance abuse \ndisorder.\n\n            Passed the House of Representatives June 19, 2018.\n\n            Attest:\n\n                                                 KAREN L. HAAS,\n\n                                                                 Clerk."
}